Top

Published in:

01-05-2011 | Case Report

Autologous stem cell transplantation in a rare multicentric Castleman disease of the plasma cell variant

Authors: Yuval Tal, Guy Haber, Matan J. Cohen, Micci Phillips, Gail Amir, Dina Ben-Yehuda, Arie Ben-Yehuda

Published in: International Journal of Hematology | Issue 5/2011

Abstract

We present a case of a 52-year-old male who was evaluated due to anorexia, persistent diarrhea, weight loss, and liver enzyme elevations, with no hematologic laboratory abnormalities. Imaging modalities revealed several tissue lesions involving the pancreas, the right kidney, and an axillary lymph node. Diagnosis of Castleman disease was reached only due to the tissue obtained from the lymph node. Chemotherapy and immunosuppression led to a short remission. The patient underwent autologous stem cell transplantation, and has since been in remission. This case demonstrates the cryptogenic and chameleon-like nature of Castleman disease. Challenges in treating Castleman disease patients reflect current limitations and the need for a greater understanding of disease pathogenesis.

Castleman B, Towne VW. Case records of the Massachusetts General Hospital: Case No. 40231. N Engl J Med. 1954;250(23):1001–5.CrossRefPubMed

Waterston A, Bower M. Fifty years of multicentric Castleman’s disease. Acta Oncol. 2004;43(8):698–704.CrossRefPubMed

Chronowski GM, Ha CS, Wilder RB, Cabanillas F, Manning J, Cox JD. Treatment of unicentric and multicentric Castleman disease and the role of radiotherapy. Cancer. 2001;92(3):670–6.CrossRefPubMed

Klein WM, Rencic A, Munshi NC, Nousari CH. Multicentric plasma cell variant of Castleman’s disease with cutaneous involvement. J Cutan Pathol. 2004;31(6):448–52.CrossRefPubMed

Miltenyi Z, Toth J, Gonda A, Tar I, Remenyik E, Illes A. Successful immunomodulatory therapy in Castleman disease with paraneoplastic Pemphigus Vulgaris. Pathol Oncol Res. 2008.

Herrada J, Cabanillas F, Rice L, Manning J, Pugh W. The clinical behavior of localized and multicentric Castleman disease. Ann Intern Med. 1998;128(8):657–62.CrossRefPubMed

Gholam D, Vantelon JM, Al-Jijakli A, Bourhis JH. A case of multicentric Castleman’s disease associated with advanced systemic amyloidosis treated with chemotherapy and anti-CD20 monoclonal antibody. Ann Hematol. 2003;82(12):766–8.CrossRefPubMed

Ocio EM, Sanchez-Guijo FM, Diez-Campelo M, et al. Efficacy of rituximab in an aggressive form of multicentric Castleman disease associated with immune phenomena. Am J Hematol. 2005;78(4):302–5.CrossRefPubMed

Beck JT, Hsu SM, Wijdenes J, et al. Brief report: alleviation of systemic manifestations of Castleman’s disease by monoclonal anti-interleukin-6 antibody. N Engl J Med. 1994;330(9):602–5.CrossRefPubMed

10.

van Rhee F, Alikhan M, Munshi N, et al. Anti-IL6 antibody (ab) based strategies improve the management of HIV negative Castleman’s disease. Blood. 2004;104:897a.

11.

Kawabata H, Tomosugi N, Kanda J, Tanaka Y, Yoshizaki K, Uchiyama T. Anti-interleukin 6 receptor antibody tocilizumab reduces the level of serum hepcidin in patients with multicentric Castleman’s disease. Haematologica. 2007;92(6):857–8.CrossRefPubMed

12.

Nishimoto N, Kanakura Y, Aozasa K, et al. Humanized anti-interleukin-6 receptor antibody treatment of multicentric Castleman disease. Blood. 2005;106(8):2627–32.CrossRefPubMed

13.

Nishimoto N, Sasai M, Shima Y, et al. Improvement in Castleman’s disease by humanized anti-interleukin-6 receptor antibody therapy. Blood. 2000;95(1):56–61.PubMed

14.

Advani R, Warnke R, Rosenberg S. Treatment of multicentric Castleman’s disease complicated by the development of non-Hodgkin’s lymphoma with high-dose chemotherapy and autologous peripheral stem-cell support. Ann Oncol. 1999;10(10):1207–9.CrossRefPubMed

15.

Ogita M, Hoshino J, Sogawa Y, et al. Multicentric Castleman disease with secondary AA renal amyloidosis, nephrotic syndrome and chronic renal failure, remission after high-dose melphalan and autologous stem cell transplantation. Clin Nephrol. 2007;68(3):171–6.CrossRefPubMed

16.

Repetto L, Jaiprakash MP, Selby PJ, Gusterson BA, Williams HJ, McElwain TJ. Aggressive angiofollicular lymph node hyperplasia (Castleman’s disease) treated with high dose melphalan and autologous bone marrow transplantation. Hematol Oncol. 1986;4(3):213–7.CrossRefPubMed

17.

Dispenzieri A, Moreno-Aspitia A, Suarez GA, et al. Peripheral blood stem cell transplantation in 16 patients with POEMS syndrome, and a review of the literature. Blood. 2004;104(10):3400–7.CrossRefPubMed

18.

Ganti AK, Pipinos I, Culcea E, Armitage JO, Tarantolo S. Successful hematopoietic stem-cell transplantation in multicentric Castleman disease complicated by POEMS syndrome. Am J Hematol. 2005;79(3):206–10.CrossRefPubMed

19.

Halac M, Ergul N, Sager S, Demir A, Buyukpinarbasli N, Sonmezoglu K. PET/CT findings in a multicentric form of Castleman’s disease. Hell J Nucl Med. 2007;10(3):172–4.PubMed

20.

Iagaru A, Mari C, Sam Gambhir S. Follicular dendritic sarcoma within a focus of Castleman’s disease. Serial FDG PET/CT in the follow up of recurrence with histopathologic confirmation. Rev Esp Med Nucl. 2007;26(1):40–5.CrossRefPubMed

21.

Pelosi E, Skanjeti A, Cistaro A, Arena V. Fluorodeoxyglucose-positron emission tomography/computed tomography in the staging and evaluation of treatment response in a patient with Castleman’s disease: a case report. J Med Case Rep. 2008;2:99.CrossRefPubMedPubMedCentral

22.

Ramos CD, Massumoto CM, Rosa MF, et al. Focal bone marrow involvement in multicentric Castleman disease demonstrated by FDG PET/CT. Clin Nucl Med. 2007;32(4):295–6.CrossRefPubMed

Title: Autologous stem cell transplantation in a rare multicentric Castleman disease of the plasma cell variant
Authors: Yuval Tal
Guy Haber
Matan J. Cohen
Micci Phillips
Gail Amir
Dina Ben-Yehuda
Arie Ben-Yehuda
Publication date: 01-05-2011
Publisher: Springer Japan
Published in: International Journal of Hematology / Issue 5/2011
Print ISSN: 0925-5710
Electronic ISSN: 1865-3774
DOI: https://doi.org/10.1007/s12185-011-0812-0

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 5/2011

Homoharringtonine as a backbone drug for the treatment of newly diagnosed pediatric acute myeloid leukemia: a report from a single institution in China

Does more intensive therapy have effects on mantle cell lymphoma? A clinical experience from the Lymphoma Treatment Study Group in Japan

Unsuspected glucose-6-phosphate dehydrogenase deficiency presenting as symptomatic methemoglobinemia with severe hemolysis after fava bean ingestion in a 6-year-old boy

Social outcomes and quality of life of childhood cancer survivors in Japan: a cross-sectional study on marriage, education, employment and health-related QOL (SF-36)

A case of T cell prolymphocytic leukemia involving blast transformation

Nilotinib as frontline therapy for patients with newly diagnosed Ph+ chronic myeloid leukemia in chronic phase: results from the Japanese subgroup of ENESTnd

Keynote webinar | Spotlight on antibody–drug conjugates in cancer